184 related articles for article (PubMed ID: 3096778)
1. Purification of epidermal plasminogen activator inhibitor.
Hibino T; Izaki S; Izaki M
FEBS Lett; 1986 Nov; 208(2):273-7. PubMed ID: 3096778
[TBL] [Abstract][Full Text] [Related]
2. Secretion of plasminogen activator inhibitor by cultured human epidermal cells.
Hashimoto K; Nishioka K; Katayama I; Yoshikawa K
Br J Dermatol; 1986 Aug; 115(2):133-8. PubMed ID: 3091060
[TBL] [Abstract][Full Text] [Related]
3. Amiloride selectively inhibits the urokinase-type plasminogen activator.
Vassalli JD; Belin D
FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
[TBL] [Abstract][Full Text] [Related]
4. Detection and partial characterization of a specific plasminogen activator inhibitor in human chondrocyte cultures.
Yamada H; Stephens RW; Nakagawa T; McNicol D
J Biochem; 1988 Dec; 104(6):960-7. PubMed ID: 3149640
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Coleman PL; Patel PD; Cwikel BJ; Rafferty UM; Sznycer-Laszuk R; Gelehrter TD
J Biol Chem; 1986 Mar; 261(9):4352-7. PubMed ID: 2936742
[TBL] [Abstract][Full Text] [Related]
6. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH
Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343
[TBL] [Abstract][Full Text] [Related]
7. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
[TBL] [Abstract][Full Text] [Related]
8. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
Wun TC; Reich E
J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
[TBL] [Abstract][Full Text] [Related]
9. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.
Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A
J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752
[TBL] [Abstract][Full Text] [Related]
10. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
Walker B; Elmore DT
Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
[TBL] [Abstract][Full Text] [Related]
11. Poly-D-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin).
Leung KC; Byatt JA; Stephens RW
Thromb Res; 1987 Jun; 46(6):767-77. PubMed ID: 3114909
[TBL] [Abstract][Full Text] [Related]
12. The plasma inhibitors of plasminogen activator, studied by a zymographic technique.
Booth NA; Anderson JA; Bennett B
Thromb Res; 1985 May; 38(3):261-7. PubMed ID: 3161209
[TBL] [Abstract][Full Text] [Related]
13. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
14. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells.
Crutchley DJ; Conanan LB
J Biol Chem; 1986 Jan; 261(1):154-9. PubMed ID: 3079753
[TBL] [Abstract][Full Text] [Related]
15. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
17. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
[TBL] [Abstract][Full Text] [Related]
19. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
Clemmensen I; Thorsen S; Müllertz S
Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
[TBL] [Abstract][Full Text] [Related]
20. Partial purification and characterization of epidermal plasminogen activator and their inhibitor.
Nakagawa M; Fukuyama K; Epstein WL; Hara A; Sawada H
Chem Pharm Bull (Tokyo); 1989 Jul; 37(7):1859-63. PubMed ID: 2509088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
